| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.0088 | 0.9 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | 0.0096 | 0.9 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |